Noneffectiveness of scopolamine for facilitating detection of upper gastrointestinal neoplasia during screening esophagogastroduodenoscopy: propensity score-matched study

Abstract

Background Antispasmodics, such as scopolamine, are widely used in several countries prior to diagnostic and screening esophagogastroduodenoscopy (EGD), with the goal of optimizing the detection of minute lesions, typically early gastric cancer (T1 lesions). The aim of this study was to determine whether scopolamine facilitates detection of gastric cancer in the screening setting.

Methods A propensity score-matched retrospective study was conducted in a tertiary referral medical center in Tokyo, Japan. Consecutive individuals (n = 40 776) underwent screening EGD between January 2011 and May 2016. All outcome lesions were diagnosed with histopathological confirmation. Detection of esophageal cancer, gastric adenoma, duodenal adenoma, and upper gastrointestinal neoplasia (UGIN) were investigated as secondary outcomes.

Results Scopolamine was used in 31 130 patients (76.3 %) and propensity score matching yielded 6625 pairs. Bivariate analysis revealed no significant association between possible confounders (age, sex, overweight, atrophic gastritis, alcohol history, smoking history, midazolam use, endoscopist biopsy rate grade, and gastric cancer in first-degree relatives) and scopolamine use. Lesions detected were 18 gastric cancers, 11 esophageal cancers, 19 gastric adenomas, 6 duodenal adenomas, and 54 UGINs, with no significant association between scopolamine use and lesion detection.

Conclusions Scopolamine use did not appear to effectively facilitate detection of gastric or esophageal cancer, gastric or duodenal adenoma, and UGIN during screening EGD. Scopolamine should be avoided until its efficacy is confirmed by a randomized controlled trial.

Publikationsverlauf

Eingereicht: 29. September 2019

Angenommen: 10. Februar 2020

Artikel online veröffentlicht:
06. April 2020

• References

• 1 Gastric cancer screening guideline based on the evaluation of effectiveness, 2014 edition. Available from (Accessed 8 August 2019): http://canscreen.ncc.go.jp/guideline/igan.html
• 2 Hamashima C. Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2018; 48: 673-683
• 3 Taniyama Y, Katanoda K, Charvat H. et al. Estimation of lifetime cumulative incidence and mortality risk of gastric cancer. Jpn J Clin Oncol 2017; 47: 1097-1102
• 4 Chiu PWY, Uedo N, Singh R. et al. An Asian consensus on standards of diagnostic upper endoscopy for neoplasia. Gut 2019; 68: 186-197
• 5 Westfall T, Westfall D. Neurotransmission: the autonomic and somatic motor nervous systems. In: Brunton L. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: The McGraw-Hill companies; 2011: 171-218
• 6 Fazio DT, Bateman JB, Christensen RE. Acute angle-closure glaucoma associated with surgical anesthesia. Arch Ophthalmol 1985; 103: 360-362
• 7 Katsube T, Kon-No S, Hamaguchi K. et al. Scopolamine raises cardiac demand in the elderly during gastrointestinal endoscopy. Hepatogastroenterology 2005; 52: 1463-1466
• 8 Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87-97
• 9 Januszewicz W, Wieszczy P, Bialek A. et al. Endoscopist biopsy rate as a quality indicator for outpatient gastroscopy: a multicenter cohort study with validation. Gastrointest Endosc 2019; 89: 1141-1149
• 10 Yao K. The endoscopic diagnosis of early gastric cancer. Ann Gastroenterol 2013; 26: 11-22
• 11 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112
• 12 Japan Esophageal Society. Japanese classification of esophageal cancer, 11th Edition: part I. Esophagus 2017; 14: 1-36
• 13 Japan Esophageal Society. Japanese classification of esophageal cCancer, 11th Edition: part II and III. Esophagus 2017; 14: 37-65
• 14 WHO Classification of Tumours Editorial Board. Digestive system tumours. WHO classification of tumours. 5. edn.. Lyon: IARC; 2019
• 15 Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424
• 16 Morgan CJ. Reducing bias using propensity score matching. J Nucl Cardiol 2018; 25: 404-406
• 17 Hedenbro JL, Frederiksen SG, Lindblom A. Anticholinergic medication in diagnostic endoscopy of the upper gastrointestinal tract. Endoscopy 1991; 23: 199-202
• 18 Interview form of scopolamine (8th edition). Available from (Accessed 8 August 2019): http://e-mr.sanofi.co.jp/
• 19 Japanese Adverse Drug Event Report database (JADER). Available from (Accessed 11 March 2019): http://www.pmda.go.jp/index.html
• 20 Parkin DM. International variation. Oncogene 2004; 23: 6329-6340
• 21 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328
• 22 Song M, Camargo MC, Weinstein SJ. et al. Family history of cancer in first-degree relatives and risk of gastric cancer and its precursors in a Western population. Gastric Cancer 2018; 21: 729-737
• 23 Forman D, Newell DG, Fullerton F. et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302-1305
• 24 Barreto-Zuniga R, Maruyama M, Kato Y. et al. Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J Gastroenterol 1997; 32: 289-294
• 25 Kaji K, Hashiba A, Uotani C. et al. Grading of atrophic gastritis is useful for risk stratification in endoscopic screening for gastric cancer. Am J Gastroenterol 2019; 114: 71-79
• 26 Lin XJ, Wang CP, Liu XD. et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol 2014; 44: 783-791
• 27 Ma K, Baloch Z, He TT. et al. Alcohol consumption and gastric cancer risk: a meta-analysis. Med Sci Monit 2017; 23: 238-246
• 28 Pandeya N, Williams GM, Sadhegi S. et al. Associations of duration, intensity, and quantity of smoking with adenocarcinoma and squamous cell carcinoma of the esophagus. Am J Epidemiol 2008; 168: 105-114
• 29 Pandeya N, Williams G, Green AC. et al. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009; 136: 1215-1224
• 30 Xie FJ, Zhang YP, Zheng QQ. et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013; 19: 6098-6107
• 31 Park JM, Huo SM, Lee HH. et al. Longer observation time increases proportion of neoplasms detected by esophagogastroduodenoscopy. Gastroenterology 2017; 153: 460-469
• 32 Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55
• 33 Cepeda MS, Boston R, Farrar JT. et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 2003; 158: 280-287